Results 121 to 130 of about 692,269 (276)

Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma

The Laryngoscope, EarlyView.
We investigated the mutational landscape and prognostic implications of recurrent/metastatic papillary thyroid carcinoma using nationwide C‐CAT data from 348 patients. CDKN2A, KMT2D, and concurrent TERT/BRAF mutations were independently associated with poorer overall survival, highlighting the potential prognostic value of comprehensive genomic ...
Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Masaru Yamashita   +3 more
wiley   +1 more source

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source

PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells

Cells
Osteosarcoma, the most common malignant bone tumor in young individuals, often exhibits poor outcomes due to MDM2-mediated suppression of the p53 pathway.
Yeongji Kim, Jin-Woo Kim, Junwon Choi, Jinhyeong Kim, Soyeon Park, Wonji Choi, Hyunju An, Jinman Kim, Minsup Kim, Sujin Choi, Jinsu Lim, Hyun Il Lee, Soonchul Lee   +12 more
doaj   +1 more source

Senotherapeutics for Knee Osteoarthritis

Medicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman, Girish Pattappa, Patrick Pann, Stephan Reppenhagen, Maximilian Rudert, Peter Angele, Denitsa Docheva   +6 more
wiley   +1 more source

MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma. [PDF]

Front Oncol, 2022
Romani A, Zauli E, Zauli G, AlMesfer S, Al-Swailem S, Voltan R.   +5 more
europepmc   +1 more source

Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: Molecular dynamics simulation and free energy analysis

, 2011
Inhibition of the MDM2-p53 interaction is considered to be a new therapeutic strategy to activate wildtype p53 in tumors. Molecular dynamics (MD) simulations followed by molecular mechanics generalized Born surface area (MM-GBSA) analyses were used to ...
Xu, Beisi, Zhu, Weiliang, Chen, Jianzhong, Wang, Jinan, Li, Guohui   +4 more
core   +1 more source

Aptamer–Based Targeted Protein Degradation: Mechanistic Principles, Delivery Strategies, and Translational Opportunities

Medicinal Research Reviews, EarlyView.
ABSTRACT Targeted elimination of pathogenic proteins remains a fundamental challenge in therapeutic intervention, particularly for proteins considered “undruggable” by conventional inhibition‐based approaches. Aptamer–based targeted protein degradation (TPD) has emerged as a versatile strategy that leverages the high specificity, structural ...
Ambrin Malik, Suyeon Son, Jaesung Lee, Ki Soo Park   +3 more
wiley   +1 more source

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction [PDF]

Disruption of the MDM2-p53 protein-protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe the use of rational, structure-guided, design in the discovery of novel isoindolinone-based MDM2 ...
Bawn RH, Castro J, Endicott JA, Fazal L, Chessari G, Revill CH, Thomas H, Wilsher N, Zhao Y, Howard S, Lunec J, Ahn JS, Cons B, St Denis J, Newell DR, Blackburn TJ, Jennings C, Zhang B, Reeks J, Hardcastle IR, Thompson NT, Hobson S, Anscome E, Griffin RJ, Noble MEM, Riedinger C, Tamanini E, Cully SJ, Hearn K, Vinkovic M, Bevan LD, Harnor S, Haggerty K, Wedge SR, Golding BT, Miller DC, Anil B, Holvey RS, Buck I, Cano C, Carbain B, Johnson CN, Williams PA   +42 more
core   +2 more sources

Protosappanin A Alleviates Atherosclerosis by Regulating the MDM2/GPX4 Axis‐Mediated Endothelial Ferroptosis

Phytotherapy Research, EarlyView.
PTA alleviates atherosclerosis by regulating the MDM2/GPX4 axis‐mediated endothelial ferroptosis. ABSTRACT Endothelial ferroptosis is a crucial pathogenic driver of atherosclerosis (AS) progression. Protosappanin A (PTA), a bioactive compound from Caesalpinia sappan L., protects cardiovascular vessels by regulating ferroptosis.
Jiamei Fu, Lin Zhu, Wenwei Yang, Mengnan Li, Zhixin Wu, Shude Sun, Yabin Zhou   +6 more
wiley   +1 more source

Ganoderic Acids Alleviate Dexamethasone‐Induced Muscle Atrophy Potentially via Regulating Protein Synthesis/Degradation, Attenuating Oxidative Stress, and Antagonizing Glucocorticoid Receptor

Phytotherapy Research, EarlyView.
This work proposes a mechanism in which ganoderic acid A (GAA), the active monomer of ganoderic acids (GA) from Ganoderma lucidum, binds to the glucocorticoid receptor (GR) to form a GR‐GAA complex, thereby inhibiting DEX‐induced GR activation. This inhibition suppresses oxidative stress (ROS, MDA and 4‐HNE) by upregulating antioxidant proteins (Nrf2 ...
Kecheng Tang, Yan Yu, Yiru Chen, Zhizhen Huang, Hang Zhang, Yun Tian, Min Li, Yue Yin, Shaowei Li, Bingchuan Liu, Baoxue Yang   +10 more
wiley   +1 more source